Dyne Therapeutics (DYN) to Release Quarterly Earnings on Tuesday

Dyne Therapeutics (NASDAQ:DYN) is projected to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect Dyne Therapeutics to post earnings of ($0.92) per share for the quarter.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $13.59 on Tuesday. Dyne Therapeutics has a 1-year low of $13.07 and a 1-year high of $47.45. The company has a market cap of $1.38 billion, a PE ratio of -3.82 and a beta of 1.11. The stock’s 50 day moving average price is $17.88 and its 200 day moving average price is $28.35.

Analysts Set New Price Targets

A number of research firms recently weighed in on DYN. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Finally, Robert W. Baird assumed coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Insider Transactions at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 20.77% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.